Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesRenerve Ltd

Renerve Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.084 AUD 0.00(0%)
Last update at 2026-11-11T22:59:00Z
VOLUME
351
Market Cap
13.88M

Momentum Score

…

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers Empliq Dermal, an acellular dermal matrix (ADM) sourced from donated human skin and designed to replace lost or damaged dermal tissue; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.08
Low
0.08
High
52 Week Price Range
0.07
Low
0.22
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Renerve Ltd (RNV.AU) is limited, and the company's core operations are not clearly described in widely available filings. Long-term growth drivers will depend on the firm's execution of any disclosed strategy, revenue diversification and market opportunities disclosed in future reports, which may benefit investors if management delivers consistent operational updates.

The principal investment risk is limited transparency combined with typical small-cap liquidity and execution risk, which could make it difficult to assess prospects and increase volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.08
Dividend Yield
-
Revenue TTM
0.51M
Revenue Per Share
0.00
Gross Profit TTM
0.27M
Debt / Equity
-
ROE
-133.13%
Net Debt
-
ROCE
-203.54%
Diluted EPS TTM
-0.04

Stock Analysis

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -5.57M -3.73M -2.98M -1.80M -1.76M
Net income -5.57M -3.73M -2.98M -1.80M -1.76M
Selling general administrative 4.46M 2.89M 2.20M 1.80M 1.11M
Gross profit 0.27M 0.24M 0.18M 0.13M 0.58M
Reconciled depreciation 0.11M 0.05M 0.15M 0.15M 0.02M
Operating income -6.52M -4.45M -3.12M -2.20M -1.76M
Interest expense 0.01M 0.25M 0.29M 0.01M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.09M 0.14M - - -
Net interest income 0.08M -0.11M -0.29M -0.01M -0.00M
Total revenue 0.51M 0.27M 0.18M 0.13M 0.58M
Cost of revenue 0.24M 0.03M 0.00M - -
Total other income expense net 0.87M 0.83M 0.42M 0.40M -
Net income from continuing ops -5.57M -3.73M -2.98M -1.80M -1.76M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 4.53M 6.19M 7.92M 0.00M 0.00M
Intangible assets 0.08M 0.02M 0.01M - -
Other current assets 0.33M 0.14M 0.08M - -
Total liab 1.36M 1.00M 0.50M 0.00M 0.00M
Total stockholder equity 3.18M 5.20M 7.42M 0.00M 0.00M
Other current liab - 0.11M 0.04M - -
Capital stock 19.38M 17.02M 16.67M - -
Retained earnings -17.71M -12.19M -9.69M - -
Cash 1.49M 4.75M 7.49M - -
Total current liabilities 1.33M 0.96M 0.48M 0.00M 0.00M
Short long term debt 0.08M - - - -
Total current assets 4.17M 6.07M 7.82M 0.00M 0.00M
Long term investments 0.06M 0.04M - - -
Net receivables 0.18M 0.04M 0.06M - -
Inventory 0.07M 0.20M 0.18M - -
Accounts payable 0.26M 0.41M 0.17M - -
Non currrent assets other - - 0.04M - -
Non current assets total 0.37M 0.12M 0.10M 0.00M 0.00M
Capital lease obligations 0.12M - 0.02M - -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - 0.51M -0.56M -0.12M
Net borrowings -0.08M 0.76M 0.91M - -
Total cash from financing activities 2.76M 7.09M 0.82M 2.00M 1.52M
Net income -5.57M -3.73M -2.98M -1.80M -1.76M
Change in cash -3.18M 4.04M -0.97M -0.03M -0.46M
Begin period cash flow 4.75M 0.71M 1.68M 1.71M 2.17M
End period cash flow 1.49M 4.75M 0.71M 1.68M 1.71M
Issuance of capital stock 3.20M 7.00M - 2.21M 1.63M
Sale purchase of stock - - - -0.14M -0.10M
Capital expenditures 0.15M 0.07M 0.00M 0.05M 0.12M
Free cash flow -5.95M -3.05M -2.30M -1.52M -1.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
RNV
Renerve Ltd		 -
-%		 0.08 - - 27.20 4.53 25.70
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28

Profile*

Renerve Ltd

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers Empliq Dermal, an acellular dermal matrix (ADM) sourced from donated human skin and designed to replace lost or damaged dermal tissue; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

157 Heidelberg Road, Northcote, VIC, Australia, 3070

61 3 9482 3940

https://renerve.com.au

Name Title Year Born
Dr. Julian John Chick BSc (Hons) CEO & Executive Director 1969
Dr. David Ian Rhodes CSO & Executive Director NA
Mr. David Lilja CTA, M.B.A. CFO & Company Secretary NA
Dr. Alex Adamides FRACS, M.D. Chief Medical Officer & Member of Scientific Advisory Board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…